BioCryst Pharmaceuticals, Inc. $BCRX Shares Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 106.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 233,354 shares of the biotechnology company’s stock after acquiring an additional 120,350 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in BioCryst Pharmaceuticals were worth $1,820,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Phocas Financial Corp. acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $1,956,000. Vanguard Group Inc. raised its stake in BioCryst Pharmaceuticals by 6.1% during the 3rd quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock valued at $165,393,000 after purchasing an additional 1,246,633 shares during the period. Aberdeen Group plc acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $7,126,000. Public Sector Pension Investment Board acquired a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at $2,010,000. Finally, GSA Capital Partners LLP raised its stake in BioCryst Pharmaceuticals by 70.7% during the 3rd quarter. GSA Capital Partners LLP now owns 190,294 shares of the biotechnology company’s stock valued at $1,444,000 after purchasing an additional 78,827 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $9.02 on Friday. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -5.07 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.31. The company’s fifty day moving average price is $9.16 and its two-hundred day moving average price is $7.91.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The business had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.20 earnings per share. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post 0.31 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Needham & Company LLC dropped their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Citizens Jmp upped their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Evercore assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price target on the stock. Finally, Royal Bank Of Canada dropped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.70.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the transaction, the insider directly owned 400,703 shares of the company’s stock, valued at $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.10% of the stock is owned by insiders.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.